Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Arq. neuropsiquiatr ; 75(3): 142-146, Mar. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-838885

RESUMO

ABSTRACT The enzyme glutamic acid decarboxylase (GAD), present in GABAergic neurons and in pancreatic beta cells, catalyzes the conversion of gamma-aminobutyric acid (GABA). The cerebellum is highly susceptible to immune-mediated mechanisms, with the potentially treatable autoimmune cerebellar ataxia associated with the GAD antibody (CA-GAD-ab) being a rare, albeit increasingly detected condition. Few cases of CA-GAD-ab have been described. Methods This retrospective and descriptive study evaluated the clinical characteristics and outcomes of patients with CA-GAD-ab. Result Three patients with cerebellar ataxia, high GAD-ab titers and autoimmune endocrine disease were identified. Patients 1 and 2 had classic stiff person syndrome and insidious-onset cerebellar ataxia, while Patient 3 had pure cerebellar ataxia with subacute onset. Patients received intravenous immunoglobulin therapy with no response in Patients 1 and 3 and partial recovery in Patient 2. Conclusion CA-GAD-ab is rare and its clinical presentation may hamper diagnosis. Clinicians should be able to recognize this potentially treatable autoimmune cerebellar ataxia.


RESUMO A enzima ácido glutâmico descarboxilase (GAD), presente nos neurônios GABAérgicos e células beta do pâncreas, catalisa a conversão do ácido gama-aminobutírico (GABA). O cerebelo é altamente susceptível a mecanismos imunomediados, sendo a ataxia cerebelar associada ao anticorpo anti-GAD (CA-GAD) uma doença potencialmente tratável. Embora rara, sua frequência é crescente, com poucos casos descritos. Métodos Estudo retrospectivo e descritivo avaliando características clínicas e desfechos da CA-GAD. Resultados Três pacientes com CA-GAD, altos títulos de anti-GAD e doença endócrina autoimune foram identificados. Os pacientes 1 e 2 tinham síndrome da pessoa rígida em forma clássica e apresentação insidiosa da ataxia cerebelar, enquanto o paciente 3 tinha ataxia cerebelar pura e apresentação subaguda. Os pacientes 1 e 3 não melhoraram com imunoglobulina intravenosa e o paciente 2 teve recuperação parcial. Conclusão A CA-GAD é rara e pode ter apresentação clínica desafiadora. Os médicos devem ser capazes de reconhecer essa forma potencialmente tratável de ataxia cerebelar autoimune.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Autoanticorpos/sangue , Ataxia Cerebelar/complicações , Glutamato Descarboxilase/sangue , Imageamento por Ressonância Magnética , Ataxia Cerebelar/diagnóstico , Ataxia Cerebelar/imunologia , Ataxia Cerebelar/tratamento farmacológico , Estudos Retrospectivos , Resultado do Tratamento , Imunoglobulinas Intravenosas/uso terapêutico , Glutamato Descarboxilase/imunologia
2.
Medicina (B.Aires) ; 73 Suppl 1: 49-54, 2013.
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-1165148

RESUMO

Autosomal recessive cerebellar ataxias belong to a broader group of disorders known as inherited ataxias. In most cases onset occurs before the age of 20. These neurological disorders are characterized by degeneration or abnormal development of the cerebellum and spinal cord. Currently, specific treatment is only available for some of the chronic ataxias, more specifically those related to a known metabolic defect, such as abetalipoproteinemia, ataxia with vitamin E deficiency, and cerebrotendinous xanthomatosis. Treatment based on a diet with reduced intake of fat, supplementation of oral vitamins E and A, and the administration of chenodeoxycholic acid could modify the course of the disease. Although for most of autosomal recessive ataxias there is no definitive treatment, iron chelators and antioxidants have been proposed to reduce the mitochondrial iron overload in Friederich’s ataxia patients. Corticosteroids have been used to reduce ataxia symptoms in ataxia telangiectasia. Coenzyme Q10 deficiency associated with ataxia may be responsive to Co Q10 or ubidecarenone supplementations. Early treatment of these disorders may be associated with a better drug response.


Assuntos
Ataxia Cerebelar/tratamento farmacológico , Ataxia Cerebelar/etiologia , Ataxia de Friedreich/tratamento farmacológico , Ataxia/tratamento farmacológico , Corticosteroides/uso terapêutico , Debilidade Muscular/tratamento farmacológico , Deficiência de Vitamina E/complicações , Doença Crônica , Doenças Mitocondriais/tratamento farmacológico , Humanos , Proteínas de Ligação ao Ferro/fisiologia , Ubiquinona/deficiência , Vitamina E/uso terapêutico
3.
Medicina (B.Aires) ; 73 Suppl 1: 30-7, 2013.
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-1165150

RESUMO

Acute cerebellar ataxia of childhood is the most frequent neurological complication of chickenpox virus infection. Acute cerebellar ataxia is categorized within the group of acute postinfectious complications. The aims of this study were: (I) to evaluate the clinical presentation, management, and follow-up of children hospitalized due to acute cerebellar ataxia in a tertiary pediatric hospital, where immunization for chickenpox is not available, and (II) to describe the differential diagnosis of acute postinfectious cerebellitis. We evaluated 95 patients with acute cerebellar ataxia. The diagnostic criteria for acute ataxia were: Acute-onset loss of coordination or gait difficulties, with or without nystagmus, lasting less than 48 hours in a previously healthy child. All children met the inclusion criteria, except those with drug-induced ataxia in whom duration should be less than 24 hours for inclusion in the study. The data were recorded in a clinical pediatrics and neurological chart. Among immunosuppressed patients acute cerebellar ataxia was most frequently due to chickenpox. Most of the patients were male. Age at presentation ranged from preschool to 5 years of age. Time lapse between presentation of the rash and hospital admission ranged from 1 to 3 days. CSF study was performed in 59.5


of the cases. Brain magnetic resonance imaging and computed tomography scan showed edema in 33.3


. Intravenous acyclovir was used in 23 patients, however, no significant differences were found in clinical manifestations and follow-up between treated and untreated patients. Ataxia was the first clinical manifestation. Mean hospital stay ranged from 2 to 11 days with a mean of 4 days.


Assuntos
Ataxia Cerebelar/diagnóstico , Ataxia Cerebelar/etiologia , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Ataxia Cerebelar/tratamento farmacológico , Criança , Diagnóstico Diferencial , Doença Aguda , Estudos Retrospectivos , Fatores de Tempo , Feminino , Humanos , Masculino
9.
Rev. chil. pediatr ; 56(2): 107-8, mar.-abr. 1985.
Artigo em Espanhol | LILACS | ID: lil-1150

RESUMO

Una niña de 8 años presentó síntomas de compromiso cerebeloso al término de la primera semana de evolución de una fiebre tifoídea demostrada con hemocultivos ymielocultivos. Los exámenes y el cultivo de líquido cefalorraquídeo dieron resultados normales. Los síntomas y signos desaparecieron después de iniciar el tratamiento con Cloramfenicol y estaban ausentes quince días después del alta


Assuntos
Criança , Humanos , Feminino , Ataxia Cerebelar/etiologia , Febre Tifoide/complicações , Ataxia Cerebelar/tratamento farmacológico , Cloranfenicol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA